This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
TheStreet Rating

10 Best Biotech Stocks for 2014

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for 2014

Biotechnology News

Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
12/18/14 10:01AM
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
12/17/14 9:20AM
Auspex is expected to seek U.S. approval for SD-809 next year.
12/16/14 4:06PM
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
12/16/14 11:20AM
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
12/15/14 11:49AM
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.
12/15/14 9:23AM
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
12/12/14 6:05AM
Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.
12/10/14 9:21AM
Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.
12/8/14 5:45PM
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
12/8/14 7:15AM
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
12/7/14 5:28PM
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
12/7/14 3:33PM
Agios and Celgene are accelerating development of AG-221 based on updated results from an early study showing strong and durable activity.
12/7/14 12:30PM
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
12/6/14 1:00PM
Checkpoint inhibitors can prime a patient's own immune system to kill certain types of blood cancer cells just like they do with solid tumors such as melanoma and lung cancer.
12/6/14 1:00PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs